NEWARK, N.J., January 24, 2025--(BUSINESS WIRE)--Prudential Financial, Inc. (NYSE: PRU) and Dai-ichi Life Holdings announced today their intent to pursue a strategic partnership focused on product ...
An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...
Prudential Financial, Inc. (NYSE: PRU) and Dai-ichi Life Holdings announced today their intent to pursue a strategic partnership focused on product distribution and asset management capabilities.
Dai-ichi Life Insurance Co. lost about ¥140 billion ($890 million) selling off bonds with longer maturities to prepare for higher interest rates. The insurer sold about ¥500 billion of Japanese ...
NEWARK, N.J., January 24, 2025--(BUSINESS WIRE)--Prudential Financial, Inc. (NYSE: PRU) and Dai-ichi Life Holdings announced today their intent to pursue a strategic partnership focused on product ...
A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback